Patents by Inventor Christiane Quiniou
Christiane Quiniou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210322509Abstract: A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof: to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.Type: ApplicationFiled: June 30, 2021Publication date: October 21, 2021Applicants: CHU SAINTE-JUSTINE, UNIVERSITÉ DE MONTRÉAL, THE UNIVERSITY OF ADELAIDEInventors: Sylvain CHEMTOB, Christiane QUINIOU, Sarah Anne ROBERTSON, Mathieu NADEAU-VALLÉE, William D. LUBELL, David OLSON, Peck Yin CHIN, Sylvie GIRARD, Doan-Ngoc DUC
-
Patent number: 10253087Abstract: The invention relates to a peptide useful as a CCR2 non-competitive antagonist peptide.Type: GrantFiled: May 1, 2018Date of Patent: April 9, 2019Assignee: Sorbonne UniversityInventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20190091279Abstract: A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.Type: ApplicationFiled: March 9, 2016Publication date: March 28, 2019Inventors: Sylvain CHEMTOB, Christiane QUINIOU, Sarah Anne ROBERTSON, Mathieu NADEAU-VALLÉE, William D. LUBELL, David OLSON, Peck Yin CHIN, Sylvie GIRARD, Doan-Ngoc DUC
-
Publication number: 20180251523Abstract: The invention relates to a peptide comprising the following amino acid sequence useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: May 1, 2018Publication date: September 6, 2018Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20170051040Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: September 2, 2016Publication date: February 23, 2017Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
-
Patent number: 9434766Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys (SEQ ID NO: 17) or Thr-Phe-Leu-Lys-Cys (SEQ ID NO: 1), useful as a CCR2 non-competitive antagonist peptide.Type: GrantFiled: June 26, 2012Date of Patent: September 6, 2016Assignee: Universite Pierre Et Marie Curie (Paris 6)Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
-
Publication number: 20150011477Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.Type: ApplicationFiled: June 26, 2012Publication date: January 8, 2015Applicant: UNIVERSITE PIERRE ET MARIE CURIEInventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
-
Patent number: 8618054Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.Type: GrantFiled: May 5, 2005Date of Patent: December 31, 2013Assignees: Valorisation-Rechereche Société en Commandite, Valorisation HSJ, Société en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
-
Publication number: 20110144014Abstract: The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Applicant: CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINEInventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20110014128Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.Type: ApplicationFiled: July 15, 2010Publication date: January 20, 2011Inventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20100190710Abstract: The present invention relates to IL-23 receptor antagonists and agonists. The use of IL-23 receptor antagonists in treating autoimmune and inflammatory disorders, as well as methods of identifying IL-23 receptor antagonists and agonists.Type: ApplicationFiled: July 7, 2008Publication date: July 29, 2010Applicant: Valorisation HSJ, Societe en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell
-
Publication number: 20100041609Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.Type: ApplicationFiled: October 15, 2009Publication date: February 18, 2010Applicant: Valorisation-Recherche, Societe en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
-
Publication number: 20090104706Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.Type: ApplicationFiled: September 11, 2008Publication date: April 23, 2009Inventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20090048161Abstract: The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis.Type: ApplicationFiled: May 5, 2006Publication date: February 19, 2009Applicant: Valorisation HSJ, Societe en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Patent number: 7432341Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.Type: GrantFiled: October 24, 2003Date of Patent: October 7, 2008Assignee: Valo HSJ, Limited PartnershipInventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20070037210Abstract: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed.Type: ApplicationFiled: October 24, 2003Publication date: February 15, 2007Inventors: Sylvain Chemtob, Christiane Quiniou, Martin Beauchamp
-
Publication number: 20060094663Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.Type: ApplicationFiled: May 5, 2005Publication date: May 4, 2006Inventors: Sylvain Chemtob, Christiane Quiniou, William Lubell, Martin Beauchamp, Karl Hansford